FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176158657> ?p ?o ?g. }

• W3176158657 endingPage "100993" @default.
• W3176158657 startingPage "100993" @default.
• W3176158657 abstract "BackgroundTenofovir and emtricitabine interfere with the SARS CoV-2 ribonucleic acid (RNA)-dependent RNA polymerase (RdRp). Several cohorts reported that people treated by tenofovir disoproxil fumarate and emtricitabine are less likely to develop SARS CoV-2 infection and related severe COVID-19.MethodsWe conducted a pilot randomized, open-label, controlled, phase 2 trial at two hospitals in France. Eligible patients were consecutive outpatients (aged ≥18 years) with RT-PCR-confirmed SARS-CoV-2 infection and an interval from symptom onset to enrolment of 7 days or less. Patients were randomly assigned in a 1:1 ratio to receive oral tenofovir disoproxil fumarate and emtricitabine (2 pills on day 1 followed by 1 pill per day on days 2–7) or the standard of care. The primary and secondary endpoints were SARS-CoV-2 viral clearance from baseline assessed by cycle threshold (Ct) RT-PCR on nasopharyngeal swab collected at day 4 and day 7, respectively. A higher Ct corresponds to a lower SARS CoV-2 viral burden. Other endpoints were the time to recovery and the number of adverse events. This trial is registered with ClinicalTrials.gov, NCT04685512.FindingsFrom November, 20th 2020 to March, 19th 2021, 60 patients were enrolled and randomly assigned to a treatment group (30 to tenofovir disoproxil fumarate and emtricitabine and 30 to standard of care). The median number of days from symptom onset to inclusion was 4 days (IQR 3–5) in both groups. Amongst patients who received tenofovir disoproxil fumarate, the difference from standard of care in the increase in Ct RT-PCR from baseline was 2.3 (95% confidence interval [-0.6 to 5.2], p = 0.13) at day 4 and 2.9 (95% CI [0.1 to 5.2], p = 0.044) at day 7. At day 7, 6/30 in the tenofovir disoproxil fumarate and emtricitabine group and 3/30 in the standard of care group reported no COVID-related symptoms. Adverse events included 11 cases of gastrointestinal side effects (grade ≤ 2), three of which leaded to drug discontinuation. Three patients had COVID-19 related hospitalisation, no participant died.InterpretationIn this pilot study of outpatients adult with recent non-severe COVID-19, tenofovir disoproxil fumarate plus emtricitabine appeared to accelerate the natural clearance of nasopharyngeal SARS-CoV-2 viral burden. These findings support the conduct of larger trials of tenofovir-based therapies for the prevention and early treatment of COVID-19.FundingNo external funding." @default.
• W3176158657 created "2021-07-05" @default.
• W3176158657 creator A5009816245 @default.
• W3176158657 creator A5027642623 @default.
• W3176158657 creator A5029201551 @default.
• W3176158657 creator A5032230986 @default.
• W3176158657 creator A5036772575 @default.
• W3176158657 creator A5043706594 @default.
• W3176158657 creator A5046800968 @default.
• W3176158657 creator A5049448682 @default.
• W3176158657 creator A5049653540 @default.
• W3176158657 creator A5055751945 @default.
• W3176158657 creator A5057962490 @default.
• W3176158657 creator A5063050466 @default.
• W3176158657 creator A5066430711 @default.
• W3176158657 creator A5069098755 @default.
• W3176158657 creator A5077818599 @default.
• W3176158657 date "2021-08-01" @default.
• W3176158657 modified "2023-09-29" @default.
• W3176158657 title "Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial" @default.
• W3176158657 cites W1970506670 @default.
• W3176158657 cites W1990567474 @default.
• W3176158657 cites W2048379351 @default.
• W3176158657 cites W2080807877 @default.
• W3176158657 cites W2134537454 @default.
• W3176158657 cites W2136230829 @default.
• W3176158657 cites W2158425153 @default.
• W3176158657 cites W2319917590 @default.
• W3176158657 cites W2330556169 @default.
• W3176158657 cites W3003951199 @default.
• W3176158657 cites W3012588029 @default.
• W3176158657 cites W3017125154 @default.
• W3176158657 cites W3019291397 @default.
• W3176158657 cites W3020773974 @default.
• W3176158657 cites W3022649665 @default.
• W3176158657 cites W3027382706 @default.
• W3176158657 cites W3030989584 @default.
• W3176158657 cites W3040216657 @default.
• W3176158657 cites W3041494167 @default.
• W3176158657 cites W3043114273 @default.
• W3176158657 cites W3043308024 @default.
• W3176158657 cites W3043764490 @default.
• W3176158657 cites W3045003495 @default.
• W3176158657 cites W3048714202 @default.
• W3176158657 cites W3048900769 @default.
• W3176158657 cites W3080808763 @default.
• W3176158657 cites W3083338864 @default.
• W3176158657 cites W3088096903 @default.
• W3176158657 cites W3089094108 @default.
• W3176158657 cites W3089261974 @default.
• W3176158657 cites W3096658347 @default.
• W3176158657 cites W3097513055 @default.
• W3176158657 cites W3116298071 @default.
• W3176158657 cites W3126652124 @default.
• W3176158657 cites W3135214788 @default.
• W3176158657 cites W3138734145 @default.
• W3176158657 cites W3141665934 @default.
• W3176158657 cites W3153372844 @default.
• W3176158657 cites W3157063593 @default.
• W3176158657 doi "https://doi.org/10.1016/j.eclinm.2021.100993" @default.
• W3176158657 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8235994" @default.
• W3176158657 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34222849" @default.
• W3176158657 hasPublicationYear "2021" @default.
• W3176158657 type Work @default.
• W3176158657 sameAs 3176158657 @default.
• W3176158657 citedByCount "39" @default.
• W3176158657 countsByYear W31761586572021 @default.
• W3176158657 countsByYear W31761586572022 @default.
• W3176158657 countsByYear W31761586572023 @default.
• W3176158657 crossrefType "journal-article" @default.
• W3176158657 hasAuthorship W3176158657A5009816245 @default.
• W3176158657 hasAuthorship W3176158657A5027642623 @default.
• W3176158657 hasAuthorship W3176158657A5029201551 @default.
• W3176158657 hasAuthorship W3176158657A5032230986 @default.
• W3176158657 hasAuthorship W3176158657A5036772575 @default.
• W3176158657 hasAuthorship W3176158657A5043706594 @default.
• W3176158657 hasAuthorship W3176158657A5046800968 @default.
• W3176158657 hasAuthorship W3176158657A5049448682 @default.
• W3176158657 hasAuthorship W3176158657A5049653540 @default.
• W3176158657 hasAuthorship W3176158657A5055751945 @default.
• W3176158657 hasAuthorship W3176158657A5057962490 @default.
• W3176158657 hasAuthorship W3176158657A5063050466 @default.
• W3176158657 hasAuthorship W3176158657A5066430711 @default.
• W3176158657 hasAuthorship W3176158657A5069098755 @default.
• W3176158657 hasAuthorship W3176158657A5077818599 @default.
• W3176158657 hasBestOaLocation W31761586571 @default.
• W3176158657 hasConcept C126322002 @default.
• W3176158657 hasConcept C142462285 @default.
• W3176158657 hasConcept C159047783 @default.
• W3176158657 hasConcept C168563851 @default.
• W3176158657 hasConcept C197934379 @default.
• W3176158657 hasConcept C2522874641 @default.
• W3176158657 hasConcept C2779778239 @default.
• W3176158657 hasConcept C2993143319 @default.
• W3176158657 hasConcept C71924100 @default.
• W3176158657 hasConceptScore W3176158657C126322002 @default.
• W3176158657 hasConceptScore W3176158657C142462285 @default.
• W3176158657 hasConceptScore W3176158657C159047783 @default.

• next